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Abstract 
Multiple Sclerosis (MS) is the autoimmune, neurodegenerative disease of the central nervous system 
(CNS). Typically, it affects the young adult population, however, up to 10% of the cases, it can 
develop in childhood. Atypical manifestations, such as the tumefactive variant (tMS) or acute 
disseminated encephalomyelitis (ADEM), especially coupled with fulminant disease course, are even 
more rare and pose a considerable differential diagnostic and therapeutic challenge. Recently, the 
therapeutic strategy on the use of disease modifying therapies (DMTs) in MS has shifted to the 
direction of a more individualized approach, that takes the personal differences heavily into account, 
in particular regard to the activity and prognosis of the disease. Despite this change has only been 
applied to adults yet, it is plausible to predict, that it will soon be applied to pediatric patients as well, 
particularly, as several randomized studies are under way concerning DMTs in pediatric populations. 
To our best knowledge, we are the first to report a successful natalizumab treatment of pediatric 
fulminant tMS, in case of a 13.5 years old girl. We feel that this report demonstrates the need of 
early and adequate treatment in such an aggressive case, because it can reverse the course of a 
possibly fatal disease. 
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Introduction 
Multiple Sclerosis (MS) is an autoimmune, demyelinating, neurodegenerative disease of the central 
nervous system (CNS). Usually it starts in young adulthood, as the majority of the patients are aged 
between 20-45 years at disease onset (1, 2). However, in a smaller proportion of cases, the disease 
manifests itself before the age of 18 years. Atypical manifestations of demyelination are even more 
rare in children: there are very few data regarding these phenomena. The options of treatment in 
pediatric onset MS (POMS), atypical manifestations variants in particular, are by far not as 
established as in adults, mainly due to the relatively low number of patients and the difficulty of 
pediatric studies (both non-interventional and interventional).  
In this short review, we aim to give a comprehensive summary of the latest findings in POMS, 
atypical variants and therapeutic approaches. Also, we aim to share our own experience on the field 
via a case-report. 
Pediatric-onset multiple sclerosis versus adult-onset multiple sclerosis 
Epidemiology 
The reported prevalence of POMS varies between 0.4-10.4% of all MS cases, with the later 
examinations yielding higher rates, possibly due to the development of better diagnostic tools and 
criteria (3). MS onset before puberty (before 10-12 years of age) is extremely rare, accounting for 
less than 1% of all cases (4-6). The mean age at disease onset tends to be around 14 years (4). The 
annual incidence rate of POMS varies between 0.07-2.90/100.000 (7, 8). The female-male ratio tends 
to be even higher than in adults, approximately 4-5:1 in POMS regarding onset around puberty, but 
interestingly in younger onset patients (before the age of 10-12 years) the distribution is near equal 
(4, 9). This highlights the possible role of sex hormones in the development of the disease (10).  
Clinical manifestations 
Overwhelming majority of pediatric MS patients develop the relapsing-remitting (RRMS) course of 
the disease, up to 98% of the patients; the primary progressive course (PPMS) is extremely rare (4, 
11). Relapses occur more frequently in POMS than in adults, the annualized relapse rate was 
consequently shown to be higher in many assessments, even during longer follow-up periods (up to 6 
years) (12, 13). There are also evidences, that the first attack interval is shorter. The relapses tend to 
be severe more often in children than in adults (8, 14). Yet, the recovery from these relapses are 
usually far better: nearly all children reach complete or near-complete recovery from the attacks (8, 
14-16). Moreover, several examinations consequently reported, that the median time to conversion 
to SPMS is approximately 10 years longer in POMS as well as the time to acquire EDSS score 4 (4, 5, 
17-19). However, once EDSS score 4 is reached, there is no difference in the disability progression 
between children and adults (4, 5, 17-19). It was also evident from these data, that POMS patients 
reach the secondary progressive (SPMS) stage 10 years younger than adult-onset MS patients (4, 5, 
17-19). There are also some differences regarding the clinical symptoms between children and 
adults. The initial relapses tend to be monofocal, and attacks involving the brain-stem and the 
cerebellum are more often seen in POMS (8, 17, 20). However, in children under the age of 10 years, 
attacks can be multifocal often, leading to difficulties in differential diagnosis from ADEM and other 
neurological conditions (4, 7, 9, 21). Other signs, as fever, headache, vomiting, altered mental status 
and seizures are present far more often in POMS than in adults (4, 22). Cognitive impairment is a 
frequent and substantial symptom of MS both in children and adults. Yet, the psychological profile is 
different than in adults: linguistic skills are much more often affected in children, as are several 
executive functions, yet dysfunction in conceptual reasoning, which is considered to be a rather MS-
specific phenomenon, is less prevalent in children (23-28). In addition, POMS patients seem to be 
vulnerable to deficits in mathematic skills, which are not seen in adults (25).  
MRI presentation 
The MRI characteristics of pediatric MS are not as clear as in adult-onset MS. Initially, it was 
established that children with MS suffer from a lower lesion burden (11). Some reports state even, 
that pediatric patients less often meet the criteria for dissemination in space (29). However, recent 
assessments proved that the T2 lesion burden is similar in POMS and in adults (21, 30). Furthermore, 
Waubant et al concluded that lesion burden on MRI scans at presentation and disease activity on 
follow-up scans in POMS patients is significantly higher, than adults at the same disease stage in the 
same population (31). They also concluded, that infratentorial lesions (including the brainstem) are 
significantly more prevalent in children (31). In accordance to this, another assessment found that 
despite the overall T1 lesion burden is lower in POMS, when evaluated regionally, POMS patients 
showed a significantly higher T1 lesion burden in the infratentorial area (21). These findings correlate 
very well with the fact, that brainstem signs are more frequently seen in children, than in adults (9).  
Several studies proved, that the negative effect on brain volume and on brain maturation is severe in 
POMS: global brain volume (as well as in adult onset MS) is significantly lower compared to the 
healthy population (30, 32). It seems that on the regional level, the thalamus is the most vulnerable 
in pediatric patients (32). Also, it seems, that this relative thalamic brain volume loss (and of the 
corpus callosum) is also indicative of cognitive dysfunction in POMS (33). 
Table 1.: The summary of differences of pediatric-onset multiple sclerosis in epidemiology, clinical 
manifestations and MRI features as compared to adult-onset multiple sclerosis 
  Pediatric-onset MS Adult-onset MS 
Epidemiology Sex ratio Before the age of 12 years, 
female-male ratio 1:1, after the 
age of 12 years, female-male ratio 
4-5:1 




98% of the patients have RRMS, 
PPMS is extremely rare 






Relapses tend to be monofocal, 
polyfocal relapses occur more 
oftenly before the age 12 years. 
Brainstem symptoms are seen 
oftenly. 
Brainstem symptoms are not 
as often present as in POMS 
Cognitive 
symptoms 
Linguistic skills, executive 
functions are more often present, 
problems with mathematic skills 
are unique to pediatric-onset 
patients. Conceptual reasoning is 
not affected. 
The most commonly affected 
cognitive domains are 
information processing 
speed, visual and verbal 
memory and attention. 
Conceptual reasoning may be 
affected 
Relapse rate The annualized relapse rate is 
higher. 







Relapses tend to be more severe, 
yet complete or near-complete 
recovery from relapses is more 
often in pediatric patients. 
Severe relapses occur less 
often than in POMS, yet the 
recovery from the relapses 
tend to be worse. 
Disability The time to reach the threshold 
associated with irreversible 
neurologic damage is ~10 years 
longer, patients reach SPMS state 
~10 years younger 
Patients reach EDSS: 4 points 




Localisation Infratentorial (mainly brainstem) 
lesion load is higher in POMS 
patients. 
Infratentorial lesions occur 
less often in adults. 
Atrophy Regional atrophy, most 
prominently the atrophy of the 
thalami is more pronounced. 
Global atrophy is the most 
prominent in adults. 
Management DMTs There are no data from 
randomized-control studies; most 
of the DMTs considered off-label 
in most countries. 
There are several DMTs 
available with data from 
randomized-control studies. 
MS, multiple sclerosis; RRMS, relapsing-remitting multiple sclerosis; SPMS, secondary progressive 
multiple sclerosis; POMS, pediatric-onset multiple sclerosis; DMT, disease modifying therapy. 
Management 
When discussing the therapy of MS, the goal is to achieve NEDA: no evidence of disease activity. This 
concept has been continuously under further development in the last couple of years: currently, 
NEDA-3 is the most widely accepted aim. NEDA-3, as the acronym suggests, defines three needs to 
be met in order to call the disease inactive: no clinical relapses, no confirmed disability progression 
and no MRI progression defined by the lack of new or enlarging T2 and T1 lesions (34). Until very 
recently, the DMTs used in MS were categorized into first-line (interferon-ß agents, glatiramer-
acetate, teriflunomide, dimethyl-fumarate) and second-line therapies (fingolimod, natalizumab, 
alemtuzumab; and the recently approved, or underway to being approved cladribine, ocrelizumab 
and daclizumab) based on the proved capability in effectiveness in comparison with the possible 
side-effects (35). Generally, first-line therapies are of moderate effectiveness with few and highly 
tolerable side-effects. In contrast, second (and third)-line therapies were characterized by strong 
effectiveness with possible side-effects being far more severe (35). Usually, first-line therapies were 
administered, and in case they were ineffective, the treatment was escalated to second-line DMTs 
(35). However, this way of thinking is changing: the new guideline, established by the European 
Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) and the European Academy 
of Neurology (EAN) suggest a novel approach to the use of DMTs. In the consensus statement of the 
members of the panel, it is stated, that “For active relapsing-remitting MS, choosing between the 
wide range of available drugs (interferon beta-1b, interferon beta-1a subcutaneously, 
intramuscularly, peginterferon beta-1a, glatiramer acetate, teriflunomide, dimethyl fumarate, 
cladribine, fingolimod, daclizumab, natalizumab and alemtuzumab) from the modestly effective to 
the highly efficacious will depend on the following factors, in discussion with the patient: 1. patient 
characteristics and comorbidities; 2. disease severity/activity; 3. drug safety profile; 4. accessibility of 
the drug” (36, 37). This statement means that the choice of the DMT is based on the individual 
characteristic of the patient at the start of the treatment and that drug safety profile is just one of 
the factors that should be considered, rather than being the most important. 
The therapeutic approach in POMS patients pose even more obstacles than in adults. As there has 
been a lack of randomized-clinical trials, there are far less data and thus, strong evidence supporting 
the use of DMTs (1, 38). The most reliable data considering pediatric patients are about the classical 
injectable therapies: interferon-ß agents and glatiramer-acetate (39, 40). There were sparse, but 
promising results considering the use of natalizumab (41, 42). Yet, none of these data came from 
randomized control studies. Until now, no valuable results were published regarding the efficacy and 
(even more importantly) safety of the orally administered DMTs or the newer monoclonal antibody 
therapies. In the last year, at the joint ECTRIMS-ACTRIMS meeting in Paris, some evidences emerged 
from retrospective studies concerning fingolimod, and it was revealed that several randomized 
studies are being conducted on several DMTs concerning pediatric patients, although we will gain 
those highly needed results years in the future (43, 44).  
However, despite the aforementioned issues, guidelines nonetheless state, that similarly to adults, 
children with MS should be started on DMTs as soon as possible, to lower the risk of early disability 
(39). Yet, in many countries, most of the DMTs are considered off-label, and thus require special 
permission to use in children. This fact complicates the management of pediatric patients, even more 
so, when the disease activity is high, culminating in the fulminant course of the disease.  
Fulminant course of demyelination is characterized by very rapid disability progression measured in 
days or a couple of weeks, with symptoms that may involve mental state alterations, increasing 
intracranial pressure, seizures and even cardiac and respiratory compromise, which can lead to a 
need for Intensive Care Unit (ICU) admission (45). Without treatment, it may be fatal in a short 
period of time. Many times, the attacks are resistant to steroid therapy (45). In these cases, plasma-
exchange therapy is needed to halt the rapid progression (45). First-line disease modifying therapies 
(DMTs) are usually not sufficient to lower the disease activity, and usually second-line DMTs should 
be used, in some cases even as an acute relapse-treatment (45, 46). 
Atypical demyelination 
Despite CNS demyelinating diseases are usually well defined, there are atypical manifestations, which 
are rare and can cause serious differential diagnostic challenge. These manifestations include acute 
disseminating encephalomyelitis (ADEM) and its hemorrhagic variant, acute hemorrhagic 
leukoencephalitis (AHLE or Weston-Hurst Syndrome); rare MS manifestations such as tumefactive 
MS (tMS), the Marburg variant, Balo’s concentric sclerosis and Schilder’s disease; and neuromyelitis 
optica spectrum disease (NMO-SD). In this review, we focus on ADEM and tMS, which are the most 
common and pose the most serious differential diagnostic problems. 
Acute disseminated encephalomyelitis 
ADEM is the most common atypical CNS demyelinating disorder in children. The incidence is 
approximately 0.4-0.8/100000, commonly it appears in children under the age of 10 (median age at 
disease onset is 5-8 years) (7, 47-51). It is more common in male patients (50, 51). It is observed, that 
the disease usually manifests after an episode of an infectious disease (usually banal) or after 
immunization (47, 52, 53). There are rare cases of adult-onset ADEM, yet there are no incidence-data 
available (45). 
MRI imaging usually shows bilateral, asymmetric, often confluating, poorly demarcated hyperintense 
lesions on the T2-weighted sequences (54). However, on T1-weighted sequences, usually no 
hypointensity can be detected (55). Typically, the central and subcortical white matter, as well as the 
cortical white-gray matter junction, the thalami, the basal ganglia, the cerebellum and the brainstem 
are involved – infratentorial lesions can be seen in approximately 50% of the patients (54, 56, 57). In 
30-85% of the cases, lesions can be detected in the spinal cord (58). Characteristically, the 
periventricular and juxtacortical white matter is spared, in contrast to MS (59, 60). However, in some 
cases tumefactive lesions has been described as well (49). Oligoclonal gammopathy (OGP) is rarely 
seen in the cerebrospinal fluid (CSF) (56).   
The diagnostic criteria have last been defined in 2013 (61): 
1. ADEM should be the first CNS event in the history of the patient with a presumed 
immunological, demyelinating cause. 
2. Symptoms are polyfocal. 
3. Encephalopathy is present, and it cannot be explained by fever, any systemic illness, or 
postictal symptoms. 
4. The presence of brain MRI abnormalities is required, that consistent with demyelination 
during the acute phase.  
5. The acute phase lasts no longer than 3 months. 
6. No new clinical or MRI findings appear 3 months or more after the clinical onset. 
Characteristically, the disease is monophasic with no resurgences of the symptoms and no new 
symptoms appearing after the initial event (61). In 2013, multiphasic disseminated encephalomyelitis 
(MDEM) was defined as two episodes of CNS attacks consistent with ADEM, separated by at least 3 
months (61). If a third relapse occurs, the suspected diagnosis is one of the chronic, relapsing CNS 
disorders, such as MS or NMO-SD (61).  
Clinically, the disease is characterized by polyfocal neurological symptoms (pyramid signs, ataxia, 
seizures, cranial nerve involvement, optic neuritis, speech disturbances or spinal cord signs) and the 
presence of encephalopathy (51). Sometimes prodromal symptoms (headache, nausea, vomiting, 
irritability, somnolence etc.) precedes the onset (51). Usually the course of the disease is fast, the 
patient reaches maximum disability within 2-5 days (54).  
In up to 25% of the cases, patients are admitted to the Intensive Care Unit (ICU) because of severe 
symptoms (62). Historically, the mortality rate of such patients was between 10-30%, due to 
respiratory failure, pneumonia, sepsis or refractory intracranial hypertension (63). Despite that, most 
of the patients recover with minimal or no neurological disability, even after comatose state or long 
period of high intracranial pressure (45). Yet, in about 30% of pediatric cases, persistent cognitive 
impairment was detected (64).   
Tumefactive multiple sclerosis 
Tumefactive MS is characterized by cerebral mass lesions with a diameter larger than 2 cm, often 
bilateral/multifocal (65). Usually they are accompanied by perilesional oedema (77%) and ring-like 
gadolinium enhancement on MRI scans (95-100%) (65, 66). In almost half of the cases, the lesion 
presents with mass effect (65). CSF examination reveals oligoclonal gammopathy (OGP) in only 11-
33% of the cases (65). Visually evoked potential (VEP) testing is positive in approximately one-third of 
the cases, while somato-sensory evoked potential (SSEP) can be positive in up to 60% of the cases 
(65).  
The etiology of tMS is largely unknown, but a B-cell mediated mechanism behind the lesions has 
been suggested in some evaluations (67). Also, both Fingolimod-therapy and the cessation of it has 
been reported as a causative agent in the development of tMS (68). The reason behind it may be 
some paradoxical CD8+ memory cell response, causing a shift from the inhibitory subset of cells to a 
subset initializing a more active immune response in the first, and an unusually strong rebound 
effect, causing a high influx of T-cells into the CNS in the second scenario (68-75). 
It is the most common type of rare MS variants, with an incidence rate of 0.3/100000 (76). In 
overwhelming majority of the cases, tumefactive lesions appear as the first attack of the disease, 
only in a low number of cases was MS diagnosed beforehand (65). The female-male ratio is similar to 
“conventional” MS, about 3:1 (68). It was proposed in a publication that tumefactive lesions may be 
overrepresented in pediatric population, yet other evaluations did not find any evidence supporting 
this claim (77, 78). Earlier studies found tMS to be extremely rare in the pediatric population (65, 78).  
Clinically, tMS is usually polysymptomatic or even presents with diffuse CNS signs (65, 79). In a 
course of just 1-2 weeks or even a couple of days the patients develop severe symptoms: usually 
motor, sensory, cerebellar and cognitive signs appear, but often aphasia, mental disturbances and 
convulsions are also present, in some cases even the intracranial pressure increases (45, 65, 79). In 
some very scarce cases, beside the CNS presentation, Guillan-Barré syndrome-like peripheral 
polyneuropathy can accompany tumefactive demyelination (53, 80). Differential diagnoses mostly 
include CNS neoplasms, malignancies, abscesses (65). The gold standard diagnostic tool is the MRI 
scan, but in some cases, even biopsy may be needed, if the diagnosis is unclear (56).  
Approximately 50% of tMS patients are proved to be resistant to steroid therapy and develop 
fulminant attacks (81). In these cases, plasma-exchange therapy is administered in order to halt the 
rapid progression (82). There were some sporadic reports of successful treatment with 
immunosuppresive agents (cyclophosphamide, rituximab), but the data are sparse and scattered 
(45). In 2013, natalizumab and mitoxantrone were also offered as potential therapies for fulminant 
MS variants (45). All in all, the management of fulminant attacks is not well established in tMS. 
Case presentation  
As it is becoming clear from the data described above, the management of POMS, atypical, fulminant 
variants in particular, is by far not as established as in “classical” MS. The evidences are sparse and 
sometimes even controversial. Because of this, we feel that any new information regarding these 
issues are highly valuable. Thus, we would like to share a case of a young girl, born in 2001 (13.5 
years old at the time of disease onset) diagnosed with fulminant tMS who received natalizumab 
therapy after the initial therapeutic approaches failed. We believe that this case is demonstrative for 
both the aforementioned issues of pediatric MS treatment and the potential of success even in 
aggressive cases. 
The patient was admitted to the ICU of the Department of Pediatrics on 3rd March 2015, after waking 
up with a left-side central facial palsy and hemiparesis (muscle strength at the time of admission was 
4/5). She had no history of any serious infectious disease and had no perinatal complications 
whatsoever in her history. Cranial MRI -performed immediately after admission- revealed multiple 
demyelinating lesions from which one, located in the right hemisphere, had a diameter of 3 cm and 
showed ring-like gadolinium enhancement. Visually Evoked Potential (VEP), lumbar puncture (LP) and 
blood tests on autoimmune vasculitis were performed. The VEP was normal, the LP showed no signs 
of acute bacterial or viral infections. Initially the girl was diagnosed with acute disseminated 
encephalomyelitis (ADEM) and mega-dose parenteral steroid therapy (3 grams over 3 days, then 
commencing a step-wise building down) was administered. She was moved from the ICU to the Unit 
of Pediatric Neurology.  
On the 8th day after admission, during the building down of corticosteroid therapy, her condition 
abruptly worsened: her left-side muscle weakness progressed from 4/5 to 1-2/5 (Expanded Disability 
Status Scale [EDSS] score: 6.5 points). An acute brain MRI was performed which showed the 
enlargement of the right hemispherical lesion and the appearance of another, vast tumefactive 
lesion in the left frontal lobe. MRI spectroscopy ruled out mitochondrial cytopathies. Meanwhile, the 
immunoblot assessment of the cerebrospinal fluid (CSF) revealed oligoclonal gammopathy (OGP). 
The blood tests on autoimmune vasculitis came back negative.  
Immediately after this worsening period, adult neurologists were consulted. Considering the 
anamnestic data, the test results, the MRI picture and the resistance to steroid therapy, the patient 
was diagnosed with the fulminant variant of tMS and plasma-exchange therapy was started. After 5 
plasma-exchanges, her neurological state stagnated. On the 16th day of admission, her second 
control MRI showed that the right hemispherical tumefactive lesion again increased in size and the 
tumefactive lesion in the left frontal lobe developed gadolinium-enhancement (Figure 1, A1). 
Because of the rapid progression and the therapy resistance of the disease, adult neurologists 
recommended natalizumab therapy for the treatment of the patient. As natalizumab is considered an 
off-label treatment in children, after thoroughly informing the patient’s family on the possible side-
effects and acquiring their written consent, the approval procedure for natalizumab was 
commenced. Meanwhile the patient received four more plasma-exchange therapies to stop the 
progression. 
The National Institute of Quality and Organizational Development in Healthcare and Medicines of 
Hungary permitted the use of natalizumab in this case. The patient received the first natalizumab 
infusion on the 27th, March 2015, the 24th day of admission. She tolerated the treatment well, no 
side-effects or allergic reactions were observed. Her condition steadily improved: the muscle 
strength increased to 4/5 again. A third control MRI was performed, which still showed the 
enlargement of the right hemispherical lesion, but also the decrease of the gadolinium 
enhancement. In improving condition, the girl was released from the Department of Pediatrics. 
In April, 2015, after the second natalizumab infusion therapy, the patient showed no sign of paresis 
whatsoever; and apart from slight hyperreflexia, Babinski-tendency and slight cerebellar ataxia on 
the left side, her neurological state was normal, the EDSS score was 1.5 points.  She scored 5.5 
seconds on the Timed-25 Foot Walk (T25-FW) and 6 minutes 43 seconds on the Timed-500 Meter 
Walk Test (T500-MW). She was assessed with the 9-Hole Peg Test (9-HPT): she scored 18.4 and 20.6 
seconds with the dominant (right) hand and 39.2 and 43.4 seconds with the non-dominant (left) 
hand respectively. Her cognitive state was evaluated with the Symbol Digit Modalities Test (SDMT) 
and the Paced Auditory Serial Addition Test (PASAT): she scored 45 points on SDMT (z-score: -0,75) 
and 35 points on PASAT. She scored 33 points on the Fatigue Impact Scale (FIS) implying a mild 
fatigue, and 8 points on the Beck’s Depression Inventory (BDI-II).  
In 2016, on her 12-months control visit, a control brain MRI was performed, which showed the 
decrease in size of the right hemispherical lesion, revealed no gadolinium-enhancement in any 
lesions and confirmed no signs of PML or other anomalies (Figure 1, A2). Her EDSS score was 1.0 
point. Her performance vastly increased as compared to the previous assessments: she finished the 
T25-FW in 4.6 seconds and the T500-MW in exactly 5 minutes. The 9-HPT scores also showed great 
improvement: her score was 22.3 and 19.6 seconds with the dominant hand and 14.5 and 23.6 
seconds with the non-dominant hand respectively. Her SDMT score increased to 63 points (z-score: 
0.87) and her PASAT performance to 54 points. Her fatigue de facto disappeared: her FIS score was 6, 
and she received only 4 points on the BDI-II assessment.  
Figure 1: MRI scans of the patient in 2015 (A1, A2) and at her 2-years control visit, 2017 (B) 
 
A1: Brain MRI taken on 3rd, March, 2015. The FLAIR sequence shows multiple demyelinating lesions 
and the left hemispherical tumefactive lesion. The T1 sequence reveals no gadolinium 
enhancement. 
A2: Brain MRI taken on 19th March, 2015. The FLAIR sequence shows multiple tumefactive lesions 
developed as compared to the previous MRI scan, the largest one being in the right hemisphere, 
largest diameter 9 cm. The T1 sequence reveals diffuse gadolinium-enhancement of the lesion in 
the right hemisphere. 
B: Brain MRI taken on 3rd, February, 2017.  The FLAIR shows that the lesions vastly decreased in 
size as compared to 2 years earlier and the T1 sequence reveals no sign of gadolinium-
enhancement. 
 
As of February, 2018, the patient has received 37 natalizumab infusions. Her EDSS score remains 
steadily on 1.0 point. She is regularly tested for JCV, so far, all her tests came back negative. On her 
24-months control MRI, the size of the lesions stagnated, there was no evidence of gadolinium-
enhancement and no sign of PML or any other anomalies, whatsoever (Figure 1, B). She did not 
worsen in any other assessed areas: she finished the T25-FW in 5 seconds, the T500-MW in 4 
minutes 22 seconds. She further improved on the 9-HPT: her scores were 18.3 and 19.9 seconds with 
the dominant hand and 21.8 and 19.3 seconds with the non-dominant hand. Her SDMT score 
increased to 73 points (z-score: 1.98), but her PASAT performance slightly lowered to 49 points. 
There was no sign of return of fatigue or depression (both FIS and BDI-II scores were 1).  
Conclusions 
Though MS is primarily the disease of adulthood, diagnosis with pediatric onset is becoming more 
and more often. The affected patients of POMS may number in the hundred-thousands worldwide, 
according to new epidemiological data (3). Despite being rare, atypical manifestations and fulminant 
disease course pose a serious differential diagnostic and therapeutic challenge. However, the global 
view on MS therapy is changing: we are moving closer to individual therapy day by day. Guidelines 
recommend to commence DMTs as early as possible, and the choice of the drugs are now based on 
several factors, the activity and severity of the disease course being one of the key points (36, 37). 
This shift in perspective was brought on by hard evidence demonstrating the benefit of early 
treatment, early change to more effective therapies and in case of aggressive disease course, the use 
of more effective DMTs as initial choice (36, 37).  
This perspective may very well be applied to POMS patients in the near future. Despite the lack of 
data from randomized control studies, existing guidelines already recommend the initiation of DMTs 
as early as possible, to halt the disease progression and reduce or stop the accumulation of disability 
in children, as existing data shows the benefit of such action (39). Luckily however, several studies 
are being conducted on pediatric patients right now, to improve our knowledge on the benefits and 
potential risks of DMTs (43).  
The presented case highlights the difficulties in diagnosis and treatment of POMS, especially in case 
of a highly active, atypical manifestation. Such an aggressive, fulminant course of MS may very well 
be fatal in a short period of time if left untreated or treated with inadequately effective methods 
(45). As many DMTs are still considered off-label in the pediatric population, sometimes the choice of 
treatment becomes hard and require additional paper-work and special permissions. However, the 
case also demonstrates the great success of such choices in these situations. To our best knowledge, 
we are the first to report successful treatment of fulminant pediatric tMS with natalizumab. 
The reviewed data and the presented case leads us to conclude, that the choice of MS therapy 
should very well be based on the individual requirements of the patient (in accordance with the new 
ECTRIMS/EAN guidelines), regardless of the patients age, because early diagnosis and effective 
treatment may reverse the disease course even in highly aggressive, potentially fatal cases. 
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